David Meeker, Rhythm Pharmaceuticals CEO

Rhythm says oral rare obe­si­ty drug clears Phase 2 test, plans tweaks to for­mu­la­tion

Rhythm Phar­ma­ceu­ti­cals said Wednes­day its oral can­di­date for a rare form of obe­si­ty pro­duced “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful” re­duc­tions in BMI in a mid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.